Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
Ola Electric shares dip 4% as CCPA seeks more documents amid probe
Ola Electric Mobility shares dropped 4% as the CCPA requested more documents for their investigation into alleged rights violations. The company faces regulatory challenges and